ISRCTN84544741已完成4 期
A phase IV, double-blind randomised placebo-controlled, parallel group multi-site trial of sertraline compared to placebo in patients presenting with depressive symptoms in primary care where treatment with SSRIs is uncertain. What are the indications for Prescribing ANtiDepressants that will leAd to a clinical benefit? (PANDA RCT)
niversity College London (UK)0 个研究点目标入组 655 人开始时间: 2014年3月20日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 655
研究概览
简要总结
2019 results in https://www.ncbi.nlm.nih.gov/pubmed/31543474 (added 25/09/2019) 2019 cost-effectiveness results in https://www.ncbi.nlm.nih.gov/pubmed/31777008 (added 02/12/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Participants presenting in primary care aged 18-74 with depressive symptoms and both the GP and patient are unsure whether there will be significant clinical benefit from taking SSRI antidepressants and not currently on antidepressants (or in previous 8 weeks).
- •The trialists want to keep the inclusion criteria pragmatic and broad to reflect the current dilemma in clinical practice. They therefore think that the uncertainty of GP and patient about the possible benefits of antidepressants is the key entry criterion for the trial. They have included participants up to 74 years as additional clinical issues concerned with cognitive decline and social care become more common after that age.
- •There may be situations where people with severe depressions would be included in the study and might receive placebo. The patient will always be free to consult their general practitioner during the study about any of their health concerns. The patient and GP can contact the PI at any time and seek advice about continuing with the study medication to stop the randomised treatment if there was deterioration or any other clinical need to start antidepressants. The trialists would allow hypnotic medication and other non-pharmacological treatment options including low intensity psychosocial treatments as provided by IAPT or counselling. The trialists will record this information and can investigate any impact on the findings in secondary analyses (and also use for the economic analysis).
- •There is marked comorbidity between depression and anxiety disorders. The trialists are relying upon the GP referring subjects into the study to exclude all anxiety disorders that they have identified and wish to treat with SSRIs. The trialists will assess anxiety disorders at baseline and any influence of comorbid anxiety (that they expect will be quite common) on outcome can be examined in exploratory analyses.
- •Target Gender: Male & Female; Upper Age Limit 74 years ; Lower Age Limit 18 years
排除标准
- •1. Anyone who is incapable of completing the questionnaires or who has other psychiatric disorders including psychosis, bipolar disorder, dementia, eating disorder, substance dependence, schizophrenia, mania, hypomania
- •2. Known allergies to the IMP, placebo or excipients
- •3. Poorly controlled epilepsy
- •4. Hepatic impairment
- •5. Currently on contraindicated medication: monoamine oxidase Inhibitors within 14 days or pimozide
- •6. Pregnant women
- •Added 07/07/2017:
- •7. People with bleeding disorders such as haemophilia, Christmas disease and von Willebrands disease, as well as those with past medical history of bleeding gastric or duodenal ulcers or other significant bleeding disorders
- •8. An episode of Torsade’s de Pointes
研究者
相似试验
终止
不适用
Morphine for the relief of breathlessness in chronic heart failure (CHF)Heart failure, including failure due to left ventricular dysfunction and failure with preserved ejection fractionCirculatory SystemISRCTN41349358Hull and East Yorkshire Hospitals NHS Trust (UK)45
已完成
不适用
Double-blind, placebo-controlled randomised trial of alpha-tocopherol and oxpentifylline in patients with radiation fibrosisCancerBreast cancerISRCTN45257322Cancer Research UK (CRUK) (UK)
已完成
3 期
A phase III randomised, double blind, placebo controlled trial of carboplatin/etoposide with or without thalidomide in small cell lung cancerSmall cell lung cancerMalignant neoplasm of bronchus or lungCancerISRCTN16174527Sponsor not defined - Record supplied by London Lung Cancer Group724
已完成
不适用
Phase III randomised, double-blind, placebo-controlled trial of Gefitinib (Iressa®) versus placebo in Oesophageal Cancer progressing after chemotherapyCancerOesophageal cancerISRCTN29580179niversity of Oxford (UK)450
已完成
不适用
Chinese herbal medicine in the treatment of women with recurrent urinary tract infectionsTopic: Primary CareSubtopic: Infectious diseases and microbiology, Primary careDisease: All DiseasesInfections and InfestationsISRCTN95402719niversity of Southampton (UK)61